For others, more expensive treatment such as CSII with and without ... are common in patients with problematic hypoglycemia; they may only be eligible for an islet transplant.

Tumor HI is a rare condition that results in hypoglycemia caused by either islet cell tumors (eg, insulinomas) or non-islet cell tumors (eg, hepatocellular carcinoma).

Rezolute, Inc. (RZLT),a late-stage biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has ...

We are thrilled with FDA’s designation, which allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI.” The FDA's Orphan Drug Designation is ...

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ...

Autopsy at the age of six and a half months showed marked islet-cell hyperplasia of the pancreas, suggesting that hyperinsulinism was the immediate cause of the hypoglycemia. Treatment with ACTH ...

Rezolute received an orphan-drug designation from the Food and Drug Administration for its treatment of hypoglycemia, or low blood sugar, caused by a disease in which a tumor produces too much insulin ...

A study conducted by a Brazilian researcher at Harvard shows that serotonin – a hormone known for regulating mood – plays a ...

Postprandial hypoglycemia is one of the main complications of bariatric surgery and can affect up to 30% of patients. Unlike ...

receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH). “We are pleased to complete the last subject visit in our Phase 1 trial of MBX 1416 in healthy adults ...

We are thrilled with FDA’s designation, which allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI.” The FDA's Orphan Drug Designation is ...